### ASCO 2020 – NRG Oncology Abstract Presentation Schedule

**Oral Presentations, Poster Discussions, and Poster Presentations**

May 29–31, 2020 • Virtual Scientific Program

- Oral, Poster Discussions, Poster Sessions, and track-based Clinical Science Symposia, will be available on demand after initial presentation
- Registrants will have exclusive access to hundreds of video and slide presentations, as well as discussant commentary for 180 days
- [Digital Program - 2020 ASCO Virtual Scientific Program](#)

<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Saturday, May 30, 2020</th>
<th>Time &amp; Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| NSABP B-50I | Biomarker data from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer  
  Presenter: Carsten Denkert  
  Abstract #: 502 | 10:30 am  
  Breast Cancer - Local/Regional/Adjuvant (Oral Abstract Session) |
| **Breast** |
| Alliance A011106/NRG collaboration | ALTERNATE: Neoadjuvant endocrine treatment approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal women: Alliance A011106  
  Presenter: Cynthia X. Ma  
  Abstract #: 504 | 10:30 am  
  Breast Cancer - Local/Regional/Adjuvant (Oral Abstract Session) |
| **Breast** |
| NSABP B-43 | Primary results of NRG Oncology / NSABP B-43: Phase III trial comparing concurrent trastuzumab and radiation therapy with RT alone for women with HER2-positive ductal carcinoma in situ after lumpectomy  
  Presenter: Melody A. Cobleigh  
  Abstract #: 508 | 10:30 am  
  Breast Cancer - Local/Regional/Adjuvant (Oral Abstract Session) |
| **Breast** |
| SWOG S1416/NRG collaboration | Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer and/or germline BRCA associated breast cancer (SWOG S1416)  
  Presenter: Priyanka Sharma  
  Abstract #: 1001 | 10:30 am  
  Breast Cancer - Metastatic (Oral Abstract Session) |
| **Oropharynx** |
| ECOG-ACRIN E3311/NRG collaboration | Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311)  
  Presenter: Robert L. Ferris  
  Abstract #: 6500 | 10:30 am  
  Head and Neck Cancer (Oral Abstract Session) |
| **Oropharyngeal** |
| NRG-HN002 | 18F FDG PET/CT prediction of treatment outcomes in patients with p16-positive, non-smoking associated, locoregionally advanced oropharyngeal cancer receiving deintensified therapy: Results from NRG-HN002  
  Presenter: Rathan Subramaniam  
  Abstract #: 6563 | 10:30 am  
  Head and Neck Cancer (Poster Session) |
| **Brain** |
| RTOG 0424 | Long-term analysis of the WHO-defined molecular subgroups of high-risk grade II gliomas treated with radiation and temozolomide on NRG Oncology/RTOG 0424  
  Presenter: Erica H. Bell  
  Abstract #: 2518 | 11:00 am  
  Central Nervous System Tumors (Poster Discussion Session) |
### Disease Site & Study #

<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Sunday, May 31, 2020</th>
<th>Time &amp; Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Brain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RTOG 1114</td>
<td></td>
<td>11:00 am</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRG-GI005</td>
<td></td>
<td>11:00 am</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACCENT/NSABP C-07, 08</td>
<td></td>
<td>11:00 am</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RTOG 1010</td>
<td></td>
<td>11:00 am</td>
</tr>
<tr>
<td><strong>Disease Site &amp; Study #</strong></td>
<td><strong>Sunday, May 31, 2020</strong></td>
<td><strong>Time &amp; Session</strong></td>
</tr>
<tr>
<td><strong>Lung</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRG-LU008</td>
<td></td>
<td>10:00 am</td>
</tr>
<tr>
<td><strong>Lung</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRG-LU005</td>
<td></td>
<td>10:00 am</td>
</tr>
<tr>
<td><strong>Lung</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECOG-ACRIN EA5161/NRG collaboration</td>
<td></td>
<td>10:00 am</td>
</tr>
<tr>
<td><strong>Ovarian</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRG-GY004</td>
<td></td>
<td>11:30 am</td>
</tr>
<tr>
<td><strong>Cervix</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOG 49, 92, 141</td>
<td></td>
<td>11:30 am</td>
</tr>
<tr>
<td><strong>Prostate</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RTOGF 3506</td>
<td></td>
<td>3:30 pm</td>
</tr>
</tbody>
</table>

#### Abstracts

- **Randomized Phase II study of rituximab, methotrexate, procarbazine, vincristine, and cytarabine with and without low-dose whole-brain radiotherapy for newly diagnosed primary CNS lymphoma**
  - **Presenter:** Antonio Omuro
  - **Abstract #:** 2501

- **Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA)**
  - **Presenter:** Van K. Morris
  - **Abstract #:** TPS4121

- **Clinicopathological and molecular biological characteristics of early onset stage II and III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients in the adjuvant colon cancer end points (ACCENT) database**
  - **Presenter:** Zhaohui Jin
  - **Abstract #:** 4099

- **Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010**
  - **Presenter:** Howard Safran
  - **Abstract #:** 4500

- **A phase III randomized trial of pleurectomy/decortication plus chemotherapy with or without adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for malignant pleural mesothelioma (MPM) (NRG-LU006)**
  - **Presenter:** Andreas Rimner
  - **Abstract #:** TPS9079

- **NRG Oncology/Alliance LU005: A phase II/III randomized clinical trial of chemoradiation versus chemoradiation plus atezolizumab in limited stage small cell lung cancer**
  - **Presenter:** Helen Ross
  - **Abstract #:** TPS9082

- **Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161**
  - **Presenter:** Ticiana A. Leal
  - **Abstract #:** 9000

- **A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer**
  - **Presenter:** Joyce F. Liu
  - **Abstract #:** 6003

- **Beyond Sedlis: A novel, histology-based nomogram for predicting recurrence risk and need for adjuvant radiation in cervical cancer—A NRG/GOG ancillary analysis**
  - **Presenter:** Kimberly Levinson
  - **Abstract #:** 6019

- **RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery**
  - **Presenter:** Edwin M. Posadas
  - **Abstract #:** TPS5601
### Renal
ECOG-ACRIN EA8143/NRG collaboration

**PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (ECOG-ACRIN EA8143)**

**Presenter:** Naomi B. Haas  
**Abstract #:** TPS5101

### PLENARY
ECOG-ACRIN E2108/NRG collaboration

**A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo Stage IV breast cancer: A trial of the ECOG-ACRIN research group. E2108**

**Presenter:** Seema A. Khan  
**Abstract #:** LBS2*

---

*MAY 28, 2020 at 5:00 pm ET - Late-breaking Abstracts (LBAs) Released on ASCO Meeting Library*

---

### Scientific Program Schedule

**Saturday, May 30, 2020**

- 9:30 AM ET: Opening Session with President's Address from Howard A. “Skip” Burris III, MD and Guest Speaker's Address by David Fajgenbaum, MD
- 10:30 AM ET: Highlights Sessions: *Breast Cancer; Head and Neck Cancer*
- 11:00 AM ET: Highlights Sessions: *Gastrointestinal Cancers; Central Nervous System Tumors*
- 11:30 AM ET: Highlights Sessions: *Hematological Malignancies; Gynecological Cancers*
- 1:00 PM ET: Special Clinical Science Symposium: *Harnessing Immunotherapy with Novel Approaches Beyond Checkpoint Inhibitors*
- 2:30 PM ET: Highlights Sessions: *Cancer Prevention, Risk Reduction, and Genetics; Symptoms and Survivorship*
- 3:30 PM ET: Special Clinical Science Symposium: *Redefining Cancer of Unknown Primary: Is Genomics the Answer?*
- 4:30 PM ET: Special Clinical Science Symposium: *Cancer Care in the time of COVID: Assessing Impact and Future Directions*

**Sunday, May 31, 2020**

- 9:30 AM ET: Highlights Sessions: *Melanoma; Health Services Research and Quality Improvement*
- 10:00 AM ET: Highlights Sessions: *Lung Cancer; Pediatric Oncology*
- 10:30 AM ET: Special Clinical Science Symposium: *Drug Development for Rare Mutations: The Opportunity to Unite and Conquer*
- 1:00 PM ET: Plenary Session
- 3:30 PM ET: Highlights Sessions: *Genitourinary Cancers; Sarcoma*
- 4:00 PM ET: Highlights Sessions: *Developmental Therapeutics; Care Delivery and Regulatory Policy*